Index S&P 500
P/E 34.48
EPS (ttm) 3.29
Insider Own 0.66%
Shs Outstand 1.73B
Perf Week -1.92%
Market Cap 195.82B
Forward P/E 21.97
EPS next Y 5.16
Insider Trans -2.56%
Shs Float 1.72B
Perf Month -2.04%
Income 5.75B
PEG 4.23
EPS next Q 1.34
Inst Own 76.62%
Short Float 0.79%
Perf Quarter -3.61%
Sales 41.22B
P/S 4.75
EPS this Y 5.28%
Inst Trans -1.00%
Short Ratio 2.70
Perf Half Y 9.36%
Book/sh 22.94
P/B 4.94
EPS next Y 10.42%
ROA 7.85%
Short Interest 13.57M
Perf Year 5.72%
Cash/sh 4.51
P/C 25.14
EPS next 5Y 8.15%
ROE 14.87%
52W Range 99.71 - 121.64
Perf YTD 3.01%
Dividend Est. 2.21 (1.95%)
P/FCF 30.19
EPS past 5Y 19.65%
ROI 10.92%
52W High -6.79%
Beta 0.73
Dividend TTM 2.20 (1.94%)
Quick Ratio 1.14
Sales past 5Y 6.10%
Gross Margin 50.98%
52W Low 13.71%
ATR (14) 1.86
Dividend Ex-Date Oct 15, 2024
Current Ratio 1.60
EPS Y/Y TTM 11.65%
Oper. Margin 16.38%
RSI (14) 37.08
Volatility 1.65% 1.53%
Employees 114000
Debt/Eq 0.38
Sales Y/Y TTM 3.15%
Profit Margin 13.94%
Recom 1.72
Target Price 131.45
Option/Short Yes / Yes
LT Debt/Eq 0.32
EPS Q/Q 14.65%
Payout 63.81%
Rel Volume 0.90
Prev Close 113.86
Sales Surprise 0.80%
EPS Surprise 0.65%
Sales Q/Q 4.85%
Earnings Oct 16 BMO
Avg Volume 5.02M
Price 113.38
SMA20 -2.56%
SMA50 -2.37%
SMA200 2.29%
Trades
Volume 4,502,874
Change -0.42%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-08-24 Initiated
Oppenheimer
Outperform
$130
Sep-19-24 Initiated
Piper Sandler
Overweight
$131
Jul-30-24 Downgrade
Edward Jones
Buy → Hold
May-30-24 Initiated
Goldman
Buy
$121
Jul-21-23 Upgrade
Wolfe Research
Underperform → Peer Perform
May-30-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$112
Apr-20-23 Reiterated
Wolfe Research
Underperform
$107 → $103
Apr-20-23 Reiterated
UBS
Buy
$117 → $130
Apr-20-23 Reiterated
Raymond James
Outperform
$116 → $123
Apr-20-23 Reiterated
JP Morgan
Overweight
$118 → $122
Apr-20-23 Reiterated
Bernstein
Outperform
$132 → $133
Apr-20-23 Reiterated
Barclays
Overweight
$125 → $127
Mar-29-23 Initiated
UBS
Buy
$117
Oct-26-22 Initiated
Mizuho
Neutral
$105
Oct-18-22 Initiated
Barclays
Overweight
$118
Oct-12-22 Initiated
Jefferies
Hold
$110
Jul-06-22 Initiated
Wolfe Research
Underperform
$95
Mar-02-22 Resumed
BofA Securities
Buy
$140
Jan-27-22 Reiterated
UBS
Buy
$138 → $142
Jan-27-22 Reiterated
Raymond James
Outperform
$150 → $143
Show Previous Ratings
Dec-13-24 01:21PM
10:58AM
Dec-12-24 09:00AM
(The Wall Street Journal)
09:00AM
(The Wall Street Journal)
Dec-11-24 05:50PM
06:01AM
Loading…
06:01AM
Dec-09-24 10:38PM
Dec-07-24 09:14PM
Dec-05-24 05:50PM
09:30AM
Dec-04-24 09:00AM
Nov-29-24 05:50PM
Nov-27-24 06:00AM
Nov-25-24 04:05PM
07:00AM
12:21PM
Loading…
Nov-22-24 12:21PM
Nov-20-24 09:00AM
Nov-19-24 09:30AM
Nov-18-24 10:00AM
06:00AM
Nov-16-24 07:19PM
Nov-14-24 06:19AM
Nov-13-24 10:28AM
06:00AM
Nov-08-24 09:16AM
04:15AM
Nov-07-24 10:39AM
Nov-05-24 09:00AM
07:26AM
Nov-04-24 06:06PM
04:09PM
Loading…
Nov-01-24 04:09PM
(Investor's Business Daily)
03:55PM
11:11AM
10:24AM
09:44AM
(The Wall Street Journal)
07:16AM
06:04AM
(The Wall Street Journal)
06:04AM
(The Wall Street Journal)
04:59AM
01:11AM
Oct-30-24 09:50AM
08:00AM
Oct-26-24 07:30AM
Oct-25-24 09:10AM
Oct-24-24 09:00AM
Oct-23-24 01:03PM
09:00AM
Oct-19-24 09:57AM
Oct-18-24 03:26PM
09:30AM
05:10AM
Oct-17-24 02:55PM
02:42PM
11:17AM
07:35AM
07:30AM
03:01AM
01:21AM
(Thomson Reuters StreetEvents)
Oct-16-24 06:41PM
04:14PM
(Investor's Business Daily)
03:47PM
02:17PM
01:45PM
12:15PM
12:14PM
12:10PM
10:49AM
10:21AM
09:30AM
09:08AM
08:40AM
08:00AM
07:58AM
(Investor's Business Daily)
07:47AM
07:38AM
(Associated Press Finance)
07:37AM
07:30AM
Oct-15-24 11:48AM
08:46AM
Oct-13-24 06:00AM
Oct-11-24 12:38PM
09:15AM
07:14AM
Oct-10-24 09:00AM
Oct-09-24 10:00AM
09:00AM
07:46AM
Oct-08-24 06:00PM
Oct-07-24 11:05AM
Oct-05-24 09:07AM
04:45AM
Oct-02-24 06:00PM
08:35AM
08:00AM
04:11AM
Oct-01-24 12:10PM
Sep-30-24 04:49AM
Sep-28-24 01:21PM
05:00AM
Sep-27-24 09:30AM
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Funck, Jr. Robert E. Officer Nov 04 '24 Proposed Sale 120.00 15,000 1,800,000 Nov 04 04:02 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Oct 21 '24 Option Exercise 47.00 157,421 7,398,787 342,227 Oct 23 05:10 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Oct 21 '24 Sale 117.04 157,421 18,424,298 184,806 Oct 23 05:10 PM ALLEN HUBERT L Officer Oct 21 '24 Proposed Sale 118.89 157,421 18,715,783 Oct 21 04:08 PM Ford Robert B CHAIRMAN AND CEO Sep 12 '24 Option Exercise 47.19 141,679 6,685,975 361,738 Sep 13 05:24 PM Ford Robert B CHAIRMAN AND CEO Sep 12 '24 Sale 116.41 141,679 16,493,218 220,059 Sep 13 05:24 PM Robert B. Ford Officer Sep 12 '24 Proposed Sale 116.41 141,679 16,492,852 Sep 12 06:20 PM MCCOY JOHN A. JR. VICE PRESIDENT Sep 04 '24 Sale 114.83 27 3,100 18,681 Sep 04 07:52 PM Funck, Jr. Robert E. Officer Sep 04 '24 Proposed Sale 115.00 30,000 3,450,000 Sep 04 04:04 PM Funck, Jr. Robert E. EXECUTIVE VICE PRESIDENT May 10 '24 Option Exercise 47.00 10,097 474,559 221,438 May 14 05:35 PM Funck, Jr. Robert E. EXECUTIVE VICE PRESIDENT May 10 '24 Sale 104.57 10,097 1,055,819 211,341 May 14 05:35 PM Earnhardt Lisa D EXECUTIVE VICE PRESIDENT May 07 '24 Sale 106.25 22,852 2,428,119 61,462 May 08 05:00 PM Salvadori Daniel Gesua Sive EXECUTIVE VICE PRESIDENT Mar 01 '24 Sale 118.50 963 114,116 125,697 Mar 04 07:18 PM Morrone Louis H. EXECUTIVE VICE PRESIDENT Mar 01 '24 Sale 118.50 801 94,918 62,968 Mar 04 07:14 PM Moreland Mary K EXECUTIVE VICE PRESIDENT Mar 01 '24 Sale 118.50 676 80,106 91,260 Mar 04 07:09 PM MCCOY JOHN A. JR. VICE PRESIDENT Mar 01 '24 Sale 118.50 472 55,932 18,760 Mar 04 07:05 PM Earnhardt Lisa D EXECUTIVE VICE PRESIDENT Mar 01 '24 Sale 118.50 694 82,239 84,314 Mar 04 06:50 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Mar 01 '24 Sale 118.50 853 101,080 184,806 Mar 04 06:39 PM Wainer Andrea F EXECUTIVE VICE PRESIDENT Feb 23 '24 Option Exercise 59.94 12,500 749,250 91,204 Feb 27 06:13 PM Wainer Andrea F EXECUTIVE VICE PRESIDENT Feb 23 '24 Sale 120.00 12,500 1,500,000 78,704 Feb 27 06:13 PM Wainer Andrea F EXECUTIVE VICE PRESIDENT Jan 29 '24 Option Exercise 50.80 42,500 2,158,950 90,027 Jan 31 05:30 PM Wainer Andrea F EXECUTIVE VICE PRESIDENT Jan 29 '24 Sale 112.50 42,500 4,781,250 65,027 Jan 31 05:30 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite